Navigation Links
New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product
Date:7/8/2009

Leading personal injury law firm files complaint, alleging permanent damage to Long Island man's sense of smell and taste

Mineola, N.Y.(Lexis Nexis) July 8, 2009 -- Marc Grossman, senior partner of leading national personal injury law firm of Sanders Viener Grossman, LLP, in Mineola, N.Y., today announced that his firm has filed a civil lawsuit against the manufacturer of the popular Zicam nasal spray and the national drugstore chain that sold the product to a New York man who is alleging permanent injuries from his use of Zicam.

The lawsuit, Coleman et al v. Matrixx Intiatives, Inc. et al (Case Number 2:09-cv-2838), was filed last Thursday in the U.S. District Court, Eastern District of New York. The complaint alleges that Donald Coleman, a Bohemia, N.Y. resident, purchased a bottle of "Zicam Cold Remedy Nasal Spray" at a CVS Pharmacy store. After using the spray for about a week, and although the label stated it was "safe and effective" and a "patented homeopathic" remedy for cold symptoms, Mr. Coleman claims that he permanently lost his senses of smell and taste.

On June 16, 2009, the U.S. Food and Drug Administration (FDA) issued a public health advisory warning consumers to stop using and discard Zicam Cold Remedy Nasal Spray products, because the agency received greater than 130 reports of Anosmia, the medical term for a loss of smell and taste. As an over-the-counter product, neither the Zicam Cold Remedy Nasal Spray nor its labeling has ever been approved by the FDA.

"This is a clear example of an unregulated and unsafe product masquerading as a product that promotes good health" said Mr. Grossman, who is representing Mr. Coleman and numerous other individuals who used Zicam. "Rather than a minor cold, Mr. Coleman now has a permanent injury that deprives him of enjoying foods and aromas that he loved. The suspected culprit is zinc gluconate, listed as the active ingredient in Zicam products."

According to Mr. Grossman, zinc has long been purported as a cure for the common cold, but clinical studies dating back to 1937 have demonstrated that the application of substances containing zinc ions to the lining of the sinuses is toxic to cells that act as "smell receptors." As these cells die, so does not only one's sense of smell, but also taste.

Sanders Viener Grossman, LLP is one of the largest national law firms specializing in protecting the rights of innocent victims who have suffered personal injury as the result of the negligence of others. The firm is well-known for its successful litigation in a wide range of personal injury and products liability cases involving allegedly defective drugs, including headline-grabbing matters against Pfizer, Merck and other leading pharmaceutical companies.

For more information about Sanders Viener Grossman, LLP, please visit www.thesandersfirm.com or call 1.800.FAIRPLAY.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2611684.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. CareFusion Files Amended Form 10 Registration Statement With SEC
2. Novo Nordisk Insulin Analogs Have Proven Safety Profiles
3. Discus Dental Files Suit to Protect BriteSmile(R) Trademark
4. WuXi PharmaTech Files 2008 Annual Report on Form 20-F
5. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
6. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
7. Watson Files FDA Application for Generic Mucinex(R) D
8. Profiles International Releases New Report on Top 5 Management Failures and Remedies for Success
9. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
10. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
11. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... MD (PRWEB) , ... May 04, 2016 , ... ... Ostomy and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy ... event promotion, time saving and planning tools to attendees and exhibitors for the ...
(Date:5/4/2016)... Gilmer, TX (PRWEB) , ... May 04, 2016 ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... 2016. SS&A teamed up with one of the top website design companies to ... contains informative legal articles related to the law firm's main practice areas. These ...
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016 According to market research ... Growth and Demand Forecast to 2022 - Industry Insights ... Field, Very High Field, Low to Mid Field, and ... Spine, Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and ... (MRI) market was valued at $5,351.7 million in 2015, ...
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: